Key result
Fetuses exposed to anti-Ro/SSA antibodies presenting with isolated endocardial fibroelastosis had near-universal outflow tract involvement, 100% survival, and low burden of AV block.
Why the study?
Anti-Ro/SSA-antibody-mediated endocardial fibroelastosis without atrioventricular block at presentation is a rare cardiac phenotype.
Observational (n=11)
Yes
Anti-Ro/SSA-antibody-mediated EFE without AV block presents with a distinct echocardiographic pattern involving the outflow tracts and has a favorable prognosis with high survival and low risk of progression to AV block.
Distinctive EFE echo pattern may aid recognition in anti-Ro/SSA fetuses without AV block; leaves open prospective validation before diagnostic adoption.
Anti-Ro/SSA-antibody-mediated endocardial fibroelastosis (EFE) without atrioventricular (AV) block at presentation is a rare cardiac phenotype. We report on 11 fetuses with this rare type of anti-Ro/SSA-antibody-mediated cardiac involvement, presenting with a distinctive echocardiographic pattern of EFE. Eleven fetuses with isolated EFE at presentation were included from four cardiac centers, and experienced fetal cardiologists reached a consensus regarding EFE location on echocardiography at presentation. Interval changes to subsequent fetal and postnatal echocardiograms were assessed to evaluate response to therapy. Echocardiographic markers of cardiac performance, including diastolic function and AV conduction, were reviewed. Ten fetuses were found to have EFE of the aortic root, proximal aorta and/or left ventricular outflow tract. In the same 10 cases, EFE of the pulmonary root, pulmonary artery and/or right ventricular outflow tract was identified. Six cases had atrial EFE and six had EFE of the crux. Four cases were known to be positive for anti-Ro/SSA antibodies prior to diagnosis, whereas, in the remaining seven, echocardiographic findings prompted testing, which was positive in all cases. The AV interval at presentation was normal in all cases, but one fetus subsequently developed AV block. Nine patients were treated with transplacental dexamethasone, five of which also received intravenous immunoglobulin (IVIG), and one received IVIG only. Of the 10 treated cases, six had improvement in EFE as shown by serial imaging and, in four cases, the severity was unchanged. All patients were liveborn. In our cohort, EFE of the aortic and pulmonary arteries and outflow tracts was nearly universal, and involvement of the atria and the crux of the heart was also common. The high survival rate and low burden of AV block are also suggestive of a distinct phenotype of anti-Ro/SSA-antibody-mediated cardiac disease with a favorable prognosis.
No takes yet. Share an insight, caveat, or question.
Keller et al. (2023) conducted an observational in Anti-Ro/SSA-antibody-mediated endocardial fibroelastosis without atrioventricular block (n=11). Anti-Ro/SSA antibodies was evaluated on Echocardiographic pattern of endocardial fibroelastosis and response to therapy. Fetuses exposed to anti-Ro/SSA antibodies presenting with isolated endocardial fibroelastosis had near-universal outflow tract involvement, 100% survival, and low burden of AV block.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: